Analysts at BMO Capital Markets said Centessa’s orexin receptor agonist has “best-in-class” potential for narcolepsy, putting ...

Investing.com — 2025年4月9日周三，Alkermes（NASDAQ: ALKS）在第24届Needham虚拟医疗保健会议上成为焦点。该公司分享了其orexin 2受体激动剂类药物的见解，强调了这些药物在治疗白天过度嗜睡方面的潜力。在强调这些药物的光明前景的同时，Alkermes也承认将志愿者数据转化为患者群体存在挑战。

For the next in our series of conditions GPs might rarely encounter, Neurology consultant Dr Clare Bolton provides an ...

Alkermes plc ALKS announced that it has initiated the phase II Vibrance-3 study, evaluating the novel, investigational and ...

Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ...

Piper Sandler analyst Biren Amin initiated coverage of Centessa (CNTA) with an Overweight rating and $38 price target The company is ...

Deutsche Bank analyst David Hoang raised the firm’s price target on Alkermes (ALKS) to $52 from $40 and keeps a Buy rating on the shares. After ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

In 1998, we purified a novel neuropeptide orexin and showed that this peptide plays pivotal roles in the regulation of appetite and sleep. In this ERATO project, we showed that the administration of ...

Orexin antagonists, meanwhile – such as Eisai's Dayvigo (lemborexant), Merck & Co's Belsomra (suvorexant) and Idorsia's recently filed daridorexant – have proved effective as treatments for ...